Hamster preproglucagon contains the sequence of glucagon and two related peptides
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glucagon is a 29-amino acid polypeptide hormone synthesized by the A cells of the endocrine pancreas. Its primary site of action is the liver where it stimulates glycogenolysis, gluconeogenesis and ketogenesis. In mammals, biosynthetic studies have shown that glucagon is derived from a precursor of molecular weight (Mr) approximately 18,000 which is five to six times larger than glucagon. Glucagon-containing polypeptides and immunoreactants of various sizes have also been described from stomach, intestine, brain and salivary gland. Here, we have determined the structure of hamster pancreatic preproglucagon from the sequence of its cDNA. This 180-amino acid precursor contains the sequence of glucagon and two glucagon-like polypeptides arranged in tandem. The precursor also contains the sequences of several non-pancreatic glucagon-containing polypeptides which suggests that, in mammals, both pancreatic and non-pancreatic glucagon and glucagon-containing polypeptides may be derived from a common precursor by tissue-specific processing. We have tentatively identified each of the glucagon-like immunoreactants which have been described with respect to the sequence of proglucagon and have proposed a scheme for the processing of pancreatic proglucagon.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, GIP-driven weight loss is synergistically enhanced by adjunct GLP-1R agonism47-49”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [48]
In the citing paper
“This highlighted for the first time that supplemental GLP-1R/GIPR co-agonism could greatly outperform GLP-1R mono-agonism, to achieve greater weight loss and elicit further improvements in glucose homeostasis48.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [48]
In the citing paper
“GIPR agonist treatment is equally effective in promoting weight loss in obese mice”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [48]
In the citing paper
“MAR709 successfully completed Phase 1 clinical trials with good tolerability48,124,125, concomitant with a meaningful reduction in body weight and HbA1c levels in subjects with T2D48,125.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [48]
In the citing paper
“There are two notable unimolecular GLP-1R/GIPR co-agonist peptides that have been preclinically and clinically most characterized to display enhanced glucose-lowering potential, superior weight loss and appetite suppression, when evaluated with comparable GLP-1R agonists.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [48]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
[57] Sequencing end-labeled DNA with base-specific chemical cleavages
Maxam, A. M., & Gilbert, W. (1980) · Methods in Enzymology · doi:10.1016/s0076-6879(80)65059-9 · Cited by 14,315
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Thomas, P. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5201 · Cited by 8,156
Atlas of protein sequence and structure
Chang, M.-Y., Dayhoff, M. O., Eck, R. V., & Sochard, M. R. (1965) · NASA Technical Reports Server (NASA) · Cited by 4,383
3′ Non-coding region sequences in eukaryotic messenger RNA
Proudfoot, N. J., & Brownlee, G. G. (1976) · Nature · doi:10.1038/263211a0 · Cited by 2,968
Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis
Beaucage, S. L., & Caruthers, M. H. (1981) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)90461-7 · Cited by 1,993
Atlas of Protein Sequence and Structure, 1966.
Hersh, R. T., Eck, R. V., & Dayhoff, M. O. (1967) · Systematic Zoology · doi:10.2307/2412074 · Cited by 1,779
Growth Hormone-Releasing Factor from a Human Pancreatic Tumor That Caused Acromegaly
Guillemin, R., Brazeau, P., Bohlen, P., Esch, F., Ling, N., & Wehrenberg, W. B. (1982) · Science · doi:10.1126/science.6812220 · Cited by 1,294
The sequence 5′-AAUAAA-3′ forms part of the recognition site for polyadenylation of late SV40 mRNAs
Fitzgerald, M. (1981) · Cell · doi:10.1016/0092-8674(81)90521-3 · Cited by 776
Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA
Comb, M., Seeburg, P. H., Adelman, J., Eiden, L., & Herbert, E. (1982) · Nature · doi:10.1038/295663a0 · Cited by 679
Research works printed but not linked: 1
- Unger, R.H. & Orei, L. (eds) Glucagon. Physiology, Pathophysiology and Morphology of the Pancreatic A-Cell (Elsevier, New York, 1981).
Cited by
Items 601–645 of 645
The Role of Transcription Factor 7-Like 2 in Hepatic Glucose Metabolism
Ip, W. (2014) · TSpace (University of Toronto)
Leen, J. (2010) · TSpace (University of Toronto)
Tv, S., Мусина, Н. Н., Ts, P., Budeeva, S. V., Гончаревич, О. К., Сергеевна, Т. Е., Dronova, I. V., & Tashireva, L. A. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00210
Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
BATAILLE, D., Chan, S. L. F., Delagrange, P., Drucker, D. J., Göke, B., Hills, R., Mayo, K. E., Miller, L. J., Salvatori, R., & Thorens, B. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f29/2019.4
“(1991) Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.”
BackgroundInfluentialCircadian Secretion of Glucagon-like Peptide-1
Martchenko, A. (2020) · TSpace (University of Toronto)
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Fukumura, K., Narimatsu, Y., Ukena, K., Furumitsu, M., Bono, H. U., & Ukena, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.27.457926
Small Molecule Libraries Used in the Development of Structure Activity Relationships
Jablonski, J. J. (2011) · doi:10.18130/v3nz8w
グルカゴン製剤におけるGlucagon-like Peptide-1免疫活性の存在
千鶴子, 大., 弘田, 明., 佐藤, 光., 橋本, 文., 大島, 一., & 島, 健. (1987) · 糖尿病 · doi:10.11213/tonyobyo1958.30.29
(2012) · CRC Press eBooks · doi:10.3109/9781841849577-3
Historical Background of Diabetic Kidney Disease
Fonseca, V. A., Bhatnagar, A., & Chamarthi, G. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_1
生細胞イメージングによる小腸内分泌L細胞からのグルカゴン様ペプチド-1分泌制御機構の解明
一貴, 原., 幹, 伊., 匠, 中., Taichi, K., & 貴司, 坪. (2020) · Comparative Endocrinology · doi:10.5983/nl2008jsce.46.101
Dillon, L. S. (1987) · Springer eBooks · doi:10.1007/978-1-4899-2007-2_7
Rajagopal, S., & Ponnusamy, M. (2018) · Springer eBooks · doi:10.1007/978-981-13-1571-8_2
(2012) · Informa Healthcare eBooks · doi:10.3109/9781841849577.002
GIP and “incretin concept”. A brief tale
Goglia, U. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.3.5
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
Catherino, W. H. (2025) · F&S Science · doi:10.1016/j.xfss.2025.01.001
Sequences of Natural Gut Peptides, Related Peptides, and Their Precursors
Yanaihara, C. (1989) · Comprehensive physiology · doi:10.1002/j.2040-4603.1989.tb01336.x · Cited by 1
Molecular Biology of Gut Peptides
Haun, R. S., Minth, C. D., Andrews, P., & Dixon, J. E. (1989) · Comprehensive physiology · doi:10.1002/j.2040-4603.1989.tb01335.x · Cited by 1
Liu, Y., Wu, H., Ma, Q., Lu, Z., Zhao, P., Li, X., Li, M., & Wen, J. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.12.002
Ahmadi, A. (2024) · eScholarship (California Digital Library)
Comparative Neuroendocrinology of Gut Peptides
Dockray, G. J. (1989) · Comprehensive physiology · doi:10.1002/j.2040-4603.1989.tb01342.x
Bitar, D. F. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Zhou, J., Pan, J.-M., Guo, H., Liu, B.-S., zhang, N., Xian, L., Zhu, K., & Zhang, D. (2026) · Fishes · doi:10.3390/fishes11040205
Schmitt, C. C. (2016) · theses.fr (ABES) · doi:10.70675/a1cd5d6azf620z4554z9020zdff30c94abab · Cited by 2
Hivelin, C. (2016) · theses.fr (ABES) · doi:10.70675/12e87c26z74c5z4ecaz93d0zad569560ff37
Peng, L., Wang, S., Sun, X., Yao, X., & Tai, W. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00041
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Rosen, C. B., & Gee, D. W. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.011
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Mechanism of action: Glucagon-like peptide-1 receptors in skin biology
Mehta, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.004
Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Amoyel, M., Carette, C., Poghosyan, T., Beyec, J. L., & Gall, M. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag032
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Glucagon-like peptide-1 regulates lipid metabolism through actions in the gut and liver
Lewis, G. F., Feng, J. N., & Jin, T. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100023
Foods as Modulators of GLP-1 Secretion
Ткаченко, Г. М., Kołodziejska, R., Rymuszka, A., Kamiński, P., & Kurhaluk, N. (2026) · Nutrients · doi:10.3390/nu18182995
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide
Tudi, K., Jie, Z., Chen, Z., Liao, W., Liu, Y., & Tang, G. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00761
Glucagon-like Peptide-1 Receptor Agonists Promote Sympathetic Innervation in Mouse Adipose Tissues
Fu, K., Deng, Z., Wu, W., Yang, J. H., & Cao, Y. (2026) · Metabolites · doi:10.3390/metabo16110813
Cytochemical Techniques in Work with Gastrointestinal Hormones
Bishop, A. E., Polak, J. M., & Bloom, S. R. (1988) · Advances in metabolic disorders · doi:10.1016/b978-0-12-027311-9.50004-4
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Metadata
- Authors
- Bell, G. I., Santerre, R. F., & Mullenbach, G. T.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- Nature
- Published
- 1983-04
- Volume
- 302
- Issue
- 5910
- Pages
- 716-718
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2061274996
- Cited by
- 649
- References
- 35
- Citations by year
- 2026: 22 · 2025: 22 · 2024: 22 · 2023: 9 · 2022: 16 · 2021: 20 · 2020: 8 · 2019: 16 · 2018: 16 · 2017: 8 · 2016: 18 · 2015: 13 · 2014: 21 · 2013: 12 · 2012: 9
- FWCI
- 41.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- proglucagon, glucagon, hamster, pancreatic A cells, cDNA sequence, precursor processing
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Fishes, Glucagon, Cricetinae, Molecular Weight, Protein Precursors, RNA, Messenger, Species Specificity, Proglucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.